You are here

Coronary side effects dash Amgen, UCB hopes for osteoporosis drug

Tuesday, May 23, 2017 - 05:50

New York

AMGEN Inc and UCB SA no longer expect their experimental osteoporosis drug to win US approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial.

The drug, romosozumab, which would be sold under the brand name

Market voices on:

Pair your daily business read with the perfect cup of espresso.

Subscribe to The Business Times today to receive your very own Nespresso Inissia coffee machine worth $188.

Find out more at

Powered by GET.comGetCom